News and Events
February 1, 2012
PROTIDE PHARMACEUTICALS RECEIVES NOTICE OF NEW TRADEMARK FOR DMSO/DEXTRAN CRYOPRESERVATIVE
Lake Zurich IL -- Milo R. Polovina, President and CEO announced today that Protide has received notice of a new trademark for it's stem cell cryopreservative, MiCordtm. The DMSO/Dextran 55%,w/v 5% w/v cryopreservative has been used worldwide for over 13 years.
JANUARY 1, 2012
PROTIDE PHARMACEUTICALS RE-INTRODUCES BALANCED SALT SOLUTIONS TO CATALOG
Lake Zurich IL -- Milo R. Polovina, President and CEO announced today that Protide has restarted manufacturing Hank's Balanced Salt Solution and Phosphate Buffered Saline Solutions for cell processing. Protide has over 25 years' experience manufacturing cell processing solutions for laboratory use. Customers requested access to our high quality solutions again while ordering from a singe source.
NOVEMBER 1, 2011
PROTIDE PHARMACEUTICALS SIGNS NEW DISTRIBUTOR
Lake Zurich IL-- Milo R. Polovina, President and CEO annouced today that Protide has entered into a distribution agreement with CedarlaneR Labs of Canada to market and distribute Protide's cryopreservation media and serum replacement products. This agreement will bolster Protide's product presence in Canada, further adding to an impressive distribution network including Funakoshi (Japan), MP Biomedicals, Sigma Aldrich, MP Biomedicals, Takara(Japan). CedarlaneR Labs focuses on products for Immunology, Molecular Biology, Cell Biology and Neurobiology.
March 27, 2011
PROTIDE PHARMACEUTICALS EMPLOYEES REGISTER WITH NMDP
Employees, friends and family of Protide Pharmaceuticals and Celox Laboratories register with the National Marrow Donor Program (NMDP). President and CEO Milo R. Polovina commented “we are pleased to support this important program and urge the participation of diverse ethnic backgrounds.”
MARCH 8, 2004
PROTIDE PHARMACEUTICALS ANNOUNCES FORM 15 FILING
ST. PAUL, MN--Protide Pharmaceuticals, Inc. (OTCBB:PPMD.OB) is announcing the filing of a Form 15 with the Securities and Exchange Commission (SEC) to terminate registration of Protide Pharmaceuticals' common stock under the Securities Exchange Act of 1934.